IMUC Key Stats
- IMUC July Options Begin Trading May 20
- ImmunoCellular Therapeutics Announces Issuance of Key Patent Covering ICT-107 Ca... May 16
- IMMUNOCELLULAR THERAPEUTICS, LTD. Files SEC form 8-K, Results of Operations and ... May 14
- 3 Biotech Stocks With Potential May 14
- ImmunoCellular Therapeutics: Marching Toward Top Line Data For ICT-107 In Q4 201... May 10
- IMMUNOCELLULAR THERAPEUTICS, LTD. Files SEC form 10-Q, Quarterly Report May 9
- ImmunoCellular Therapeutics Announces First Quarter 2013 Financial Results Business Wire May 9
- Q1 2013 IMMUNOCELLULAR THERAPEUTICS Earnings Release - After Market Close May 9
- Northwest Biotherapeutics: Moving DC Vax-L Rapidly Forward And Starting DC Vax D... May 7
- Undervaluation Of Vical's Full Pipeline Allows A Cheap Bet On Cancer Trial May 3
IMUC Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). ImmunoCellular Therapeutics is down 5.90% over the last year vs S&P 500 Total Return up 31.59%, Northwest Biotherapeutics down 10.58%, and CEL-SCI Corporation down 35.38%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for IMUC
Pro Report PDF for IMUC
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download IMUC Pro Report PDF
Pro Strategies Featuring IMUC
Did ImmunoCellular Therapeutics make it into our Pro Portfolio Strategies?